Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Eisai Gets Preliminary Injunction Against Teva Aricept Generic

This article was originally published in PharmAsia News

Executive Summary

Japan's Eisai has managed to halt Teva Pharmaceutical plans to market a generic of Eisai's Aricept (donepezil) for treating Alzheimer's disease. Eisai said a U.S. district court issued a preliminary injunction against Teva pending the outcome of a patent-infringement suit Eisai filed against the Israeli drug maker. Eisai, whose Aricept patent does not expire until 2010, said the request for the injunction was part of its effort to "protect our intellectual property throughout the world." (Click here for more

Related Content

Eisai Fights To Maintain Aricept Patent Rights While Resuming Development On Next Generation Therapy



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts